Articles Mentioning Pharmaceuticals Stocks

Results 1 - 10 of 979 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals

Investing | May 17, 2015

Is Gilead Sciences Its Own Worst Enemy?

Gilead Sciences has an amazing track record of bringing game-changing new drugs to market. Could this unique ability also be the company's biggest weakness?

Investing | May 02, 2015

Bristol-Myers Squibb Outpaces AbbVie in Hepatitis C

Bristol-Myers Squibb's hepatitis C sales topped AbbVie's in the first quarter. Is this trend set to continue?

Investing | April 28, 2015

2 Stocks to Buy in a Biotech Crash

Biopharma stocks are starting to pull back in a big way. Flamel Technologies and Pfizer, though, are two good names to pick up on any weakness. Here's why.

Investing | April 28, 2015

Bristol-Myers Squibb Crushes First-Quarter Earnings: Here's Why

Bristol-Myers posts a much stronger first quarter than expected. Here's what investors need to know.

Investing | April 25, 2015

3 Best Stocks for Investing in Generic Drugs

The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.

Investing | April 20, 2015

Is Bristol-Myers Squibb. Co. About to Fall Apart?

Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.

Investing | April 18, 2015

3 Top Healthcare Stocks Surging Higher This Year

Eagle Pharmaceuticals Inc., Esperion Therapeutics Inc., and Horizon Pharma plc have more than doubled investors' money this year.

Investing | April 16, 2015

The Best Stock to Invest in Hep C

In the multibillion-dollar market for hepatitis C, this company stands above the crowd.

Investing | April 11, 2015

The Big Pharma Stock We'd Buy and Hold for the Next 20 Years

Despite the threat of patent losses, our analysts believe these Big Pharma stocks would be smart investments over the next 20 years.

Investing | April 05, 2015

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Results 1 - 10 of 979 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals